文献速递肾移植

肾移植后eGFR下降与硬终点之间的关系

Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.
PubMed 文献 · J Am Soc Nephrol · 2016-04-08

该研究基于澳大利亚和新西兰透析与移植登记处1995至2009年的7949例肾移植受者数据,分析移植后第1至3年间eGFR百分比变化与死亡及删失死亡移植物失败的风险。结果显示,eGFR下降速率与移植物失败和死亡风险呈指数相关;eGFR下降≥30%见于10%的患者,与随后死亡(HR 2.20;95%CI 1.87-2.60)和删失死亡移植物失败(HR 5.14;95%CI 4.44-5.95)强烈相关,且优于其他替代指标。作者认为eGFR下降百分比可考虑作为肾移植试验的替代终点。

要点

  • 移植后第1至3年间eGFR下降≥30%见于10%的患者。
  • eGFR下降≥30%与随后死亡风险升高相关(HR 2.20;95%CI 1.87-2.60)。
  • eGFR下降≥30%与删失死亡移植物失败风险升高相关(HR 5.14;95%CI 4.44-5.95)。

核心结论

  • 移植后第1至3年间eGFR下降30%常见,且与随后死亡和删失死亡移植物失败风险强烈相关,与CKD中的发现一致。
  • 作者认为eGFR下降百分比应被考虑用作肾移植试验的替代终点。

研究设计与样本

  • 研究获取澳大利亚和新西兰透析与移植登记处的去标识化数据,纳入1995至2009年进行的7949例移植,包括71845患者年随访、1121例移植物丢失和1192例死亡。
  • 使用校正Cox比例风险模型分析移植后第1至3年间eGFR百分比变化与死亡或删失死亡移植物失败的风险,eGFR百分比变化以限制性立方样条建模。

主要发现

  • eGFR下降速率与移植物失败和死亡风险呈指数增加相关。
  • 与eGFR稳定相比,eGFR下降≥30%(见于10%的患者)与随后死亡强烈相关(HR 2.20;95%CI 1.87-2.60)。
  • 与eGFR稳定相比,eGFR下降≥30%与删失死亡移植物失败强烈相关(HR 5.14;95%CI 4.44-5.95)。
  • eGFR下降优于其他替代指标,包括急性排斥、血清肌酐翻倍以及第1年或第2年的eGFR。

临床怎么用

  • 作者认为eGFR下降百分比应被考虑用作肾移植试验的替代终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Trials designed to assess the effect of interventions on death and graft failure in kidney transplant recipients are not feasible, because these are predominantly late events. Here, we examined the potential of percentage decline in eGFR as a surrogate for hard outcomes. We obtained deidentified data from the Australia and New Zealand Dialysis and Transplant Registry and studied 7949 transplants performed from 1995 to 2009, including 71,845 patient-years of follow-up, 1121 graft losses, and 1192 deaths. We used adjusted Cox proportional hazards models to determine risks of death or death-censored graft failure related to percentage change in eGFR between years 1 and 3 after transplant. Percentage change in eGFR was modeled as a restricted cubic spline. Rate of eGFR decline associated with exponentially increased risks of graft failure and death. Compared with stable eGFR, a ≥30% decline in eGFR, detected in 10% of patients, strongly associated with subsequent death (hazard ratio, 2.20; 95% confidence interval, 1.87 to 2.60) and death-censored graft failure (hazard ratio, 5.14; 95% confidence interval, 4.44 to 5.95). Decline in eGFR was superior to other surrogates, including acute rejection, doubling of serum creatinine level, and eGFR at year 1 or year 2. We conclude that 30% decline in eGFR between years 1 and 3 after kidney transplant is common and strongly associated with risks of subsequent death and death-censored graft failure, which mirrors findings in CKD. Percentage decline in eGFR should be considered for use as a surrogate outcome in kidney transplant trials.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Clayton PA, Lim WH, Wong G, et al. Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants. J Am Soc Nephrol. 2016. PMID: 27059513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。